CC-90001: Clinical Trials

7 completed, 2 terminated. 7 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	7	Completed 7
Phase 2	2	Terminated 2

Follow CC-90001: new trials by email Literature Review of CC-90001 trials Research Report on CC-90001

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors BMS-986360, Docetaxel, Nivolumab - Advanced Solid Tumors	Phase 1	Completed	Bristol-Myers Squibb	70	2022-12-09	2025-06-13
Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis CC-90001, Placebo - Non-alcoholic Fatty Liver Disease, Liver Cirrhosis	Phase 2	Terminated	Celgene	56	2019-08-14	2023-06-07
A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects CC-90001 - Healthy Volunteer	Phase 1	Completed	Celgene	60	2019-04-04	2020-05-08
A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects CC-90001 - Hepatic Impairment	Phase 1	Completed	Celgene	40	2018-12-06	2020-07-27
A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects CC-90001, Omeprazole, Midazolam - Heathy Volunteer	Phase 1	Completed	Celgene	56	2017-12-04	2019-01-25
A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis CC-90001, Placebo - Idiopathic Pulmonary Fibrosis, Fibrosis	Phase 2	Terminated	Celgene	138	2017-07-26	2023-06-28
Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis CC-90001 - Pulmonary Fibrosis	Phase 1	Completed	Celgene	16	2015-08-05	2017-04-04
Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study CC-90001 - Healthy Subjects	Phase 1	Completed	Celgene Corporation	26	2014-11-01	2015-08-19
First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001 CC-90001, Placebo - Healthy Volunteers	Phase 1	Completed	Celgene Corporation	96	2014-02-01	2014-10-15

Conditions studied

Pulmonary Fibrosis (2)  ·  Fibrosis (1)  ·  Idiopathic Interstitial Pneumonias (1)  ·  Idiopathic Pulmonary Fibrosis (1)  ·  Liver Cirrhosis (1)  ·  Lung Diseases (1)  ·  Lung Diseases, Interstitial (1)  ·  Non-alcoholic Fatty Liver Disease (1)  ·  Pathologic Processes (1)  ·  Respiratory Tract Diseases (1)

Sponsors

Celgene (6)  ·  Celgene Corporation (2)  ·  Bristol-Myers Squibb (1)

Countries

United States (9)  ·  Australia (4)  ·  Canada (3)  ·  France (2)  ·  Germany (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Argentina (1)  ·  Brazil (1)  ·  Chile (1)  ·  Colombia (1)  ·  Greece (1)  ·  Italy (1)  ·  Japan (1)  ·  Mexico (1)

Top investigators

Daniel Weiss, MD (2)  ·  Ed O'Mara, MD (1)  ·  Francisco Ramirez-Valle, MD, PhD. (1)  ·  Kofi Mensah, MD, PhD (1)  ·  Ying Ye, PhD (1)

Results publications

PMID 34894681, PMID 35058236, PMID 38484130

NIH funding

2016 (1), 2018 (1)